Современные подходы к диагностике и лечению дефицита железа у больных с хронической сердечной недостаточностью

1. Scrutinio D, Passantino A, Santoro D, Catanzaro R. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. Eur J Heart Fail 2011; 13: 61–7.
2. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107: 223–5.
3. Groenveld HF, Januzzi JL, Damman K et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52 (10): 818–27.
4. Kaldara-Papatheodorou EE, Terrovitis JV, Nanas JN. Anemia in heart failure: should we supplement iron in patients with chronic heart failure? Pol Arch Med Wewn 2010; 120 (9): 354–60.
5. Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35 (7): 1737–44.
6. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41 (11): 1933–9.
7. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110 (2): 149–54.
8. Anker SD, Comin Colet J, Filippatos G et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361 (25): 2436–48.
9. Silverberg DS, Wexler D, Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 2004; 17 (6): 749–61.
10. Anand IS. Pathogenesis of anemia in cardiorenal disease. Cardiovasc Med 2005; 6 (Suppl. 3): S13–21.
11. Witte KK, Desilva R, Chattopadhyay S et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 2004; 147 (5): 924–30.
12. Scrutinio D, Passantino A, Santoro D, Catanzaro R. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. Eur J Heart Fail 2011; 13: 61–7.
13. McClellan WM, Flanders WD, Langston RD et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928–36.
14. de Silva R, Rigby AS, Witte KK et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 2006; 98: 391–8.
15. Dunlay SM, Weston SA, Redfield MS et al. Anemia and heart failure: A community study. Am J Med 2008; 121 (8): 726–32.
16. Sharma R, Francis DP, Pitt B et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25 (12): 1021–8.
17. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26 (21): 2232–7.
18. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352 (10): 1011–23.
19. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26 (4): 296–306.
20. Macdougall IC, Canaud B, de Francisco A et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail 2012; 14 (8): 882–6.
21. Jankowska EA, Rozentryt P, Witkowska A et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31 (15): 1872–80.
22. Ordway AG, Garry DJ. Myoglobin: an essential hemoprotein in striated muscle. J Exp Biol 2004; 207: 3441–6.
23. Brownlie T 4th, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004; 79: 437–43.
24. Arredondo M, Núñez MT. Iron and copper metabolism. Mol Aspects Med 2005; 26: 313–27.
25. Ortiz E, Pasquini JM, Thompson K et al. Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res 2004; 77: 681–9.
26. Weiss G, Meusburger E, Radacher G, Garimorth et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney International 2003; 64 (2): 572–8.
27. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52 (4): 727–36.
28. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74 (6): 791–8.
29. Dahl NV, Henry DH, Coyne DW. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role? Semin Dial 2008; 21 (3): 210–1.
30. Левина А.А., Казюкова Т.В., Цветаева Н.В. и др. Гепсидин как регулятор гомеостаза железа. Педиатрия. 2008; 87 (1): 67–74.
31. Nanas JN, Matsouka C, Karageorgopoulos D et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48 (12): 2485–9.
32. Stancu S, Bârsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010; 5(3): 409–16.
33. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–847.
34. Locatelli F, Covic A, Eckardt K-U et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP) Nephrol Dial Transplant 2009; 24 (2): 348–54.
35. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Кардиоваск. терапия и профилактика. 2008; 7 (6): Прил. 3.
36. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease Am J Kidney Dis 2006; 47 (5): Suppl. 3: S1–144.
37. Silverberg DS, Iaina A, Schwartz D, Wexler D. Intravenous iron in heart failure: beyond targeting anemia. Curr Heart Fail Rep 2011; 8 (1): 14–21.
38. Von Haehling S, Jankowska EA, Ponikowski P, Anker SD. Anemia in heart failure: an overview of current concepts. Future Cardiol 2011; 7 (1): 119–29.
39. Macdougall IC. Iron supplementation in the nondialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010; 26: 473–82.
40. Drakos SG, Anastasiou-Nana MI, Malliaras KG, Nanas JN. Anemia in chronic heart failure. Congest Heart Fail 2009; 15: 87–92.
41. Ngo K, Kotecha D, Walters JA et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010; (1): CD007613.
42. Van der Meer P, Lipsic E, van Gilst WH, van Veldhuisen DJ. Anemia and erythropoietin in heart failure. Heart Fail Monit 2008; 6 (1): 28–33.
43. Ghali JK, Anand IS, Abraham WT et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117 (4): 526–35.
44. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373 (9674): 1532–42.
45. McMurray JJ, Anand IS, Diaz R et al. RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009; 11 (8): 795–801.
46. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51 (2): 103–12.
47. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37 (7): 1775–80.
48. Silverberg DS, Wexler D, Blum M et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001; 21 (Suppl. 3): S236–40.
49. Bolger AP, Bartlett FR, Penston HS et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48 (6): 1225–7.
50. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50 (17): 1657–65.
51. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC et al. J Card Fail. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia 2007; 13 (1): 14–7.
52. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21 (2): 236–42.
53. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970; 100 (7): 301–3.

О.А.Эттингер, О.В.Ускова, Г.Е.Гендлин, Г.И.Сторожаков 

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ, Москва